-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Reuters·04/01/2025 11:08:20

Please log in to view news